Altimmune (ALT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $39.3 million.

  • Altimmune's Cash from Financing Activities rose 1469285.71% to $39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.8 million, marking a year-over-year increase of 8675.75%. This contributed to the annual value of $10.0 million for FY2024, which is 8833.52% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's Cash from Financing Activities is $39.3 million, which was up 1469285.71% from $52.2 million recorded in Q2 2025.
  • Altimmune's Cash from Financing Activities' 5-year high stood at $72.8 million during Q4 2023, with a 5-year trough of -$302000.0 in Q1 2023.
  • Over the past 5 years, Altimmune's median Cash from Financing Activities value was $12.5 million (recorded in 2021), while the average stood at $18.1 million.
  • The largest annual percentage gain for Altimmune's Cash from Financing Activities in the last 5 years was 16929534.88% (2023), contrasted with its biggest fall of 10949.39% (2023).
  • Altimmune's Cash from Financing Activities (Quarter) stood at $12.5 million in 2021, then tumbled by 100.34% to -$43000.0 in 2022, then skyrocketed by 169295.35% to $72.8 million in 2023, then tumbled by 86.14% to $10.1 million in 2024, then surged by 290.17% to $39.3 million in 2025.
  • Its Cash from Financing Activities stands at $39.3 million for Q3 2025, versus $52.2 million for Q2 2025 and $34.1 million for Q1 2025.